Shots:

• The US government will pay over $1B for 100M doses of its potential COVID-19 vaccine- Ad26.COV2.S- for use in the US following the US FDA’s EUA
• The government may also purchase additional 200M doses of Ad26.COV2.S under a subsequent agreement. The company is evaluating one- and two-dose regimens- in its clinical program for the global access of the vaccines
• J&J expects to meet its goal to supply 1B doses globally through the course of 2021- provided the vaccine is safe and effective. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use

­ Ref: PRNewswire | Image: PharmaShots

Related News: Johnson & Johnson Initiates P-I/IIa Study of its Ad26.COV2.S Against COVID-19 in the US and Belgium